x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

pharmaphorum Podcast

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for

science life sciences

All Episodes

11:25

FH25: On healthcare innovation with Gary Monk

pharmaphorum Podcast ·

2025/09/24

This year marks the 10th anniversary of Frontiers Health.In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk. Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that. Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.

en-us

11:04

FH25: The art of connection at Frontiers Health with...

pharmaphorum Podcast ·

2025/09/19

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector – a phrase that she says encapsulates both her personal mission and her 15 years of experience in the industry. Noizet has built her career on connecting emerging start-ups

en-us

35:41

Policy in Focus: Trump’s Most Favoured Nations drug...

pharmaphorum Podcast ·

2025/09/18

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously. In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our go-to expert on US

en-us

12:54

FH25: Exploring the intersection of patients, HCPs,...

pharmaphorum Podcast ·

2025/09/17

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0. Having spent more than two decades working at the intersection of healthcare professionals, patients, and technology, Silber has had a front row seat to the evolution of digital tools in the sector. From the

en-us

10:39

Doing good in people’s lives: Amy Burroughs discusses...

pharmaphorum Podcast ·

2025/09/11

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, and the wider oncological landscape today. You can also listen to episode 205a of the pharmaphorum

en-us

9:12

FH25: Individual centric investing with Steve Seuntjens

pharmaphorum Podcast ·

2025/09/10

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital. Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful when the outcome is more engaged people, improved health results, and ultimately reduced costs. That, he believes, is where the true value of healthcare

en-us

17:17

Pharma and health advertising: Brian Coane on the...

pharmaphorum Podcast ·

2025/09/09

When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fear of getting it wrong. After all, dull ads can lead to the dreaded ‘beige tax’. You can also listen to episode 204a of the pharmaphorum podcast in the

en-us

26:11

The glimmer of opportunity behind the storm: Ali...

pharmaphorum Podcast ·

2025/09/05

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm’ in biotech and why the skies might not be quite as grey and

en-us

10:11

FH25: The intersection of tech, science & design with...

pharmaphorum Podcast ·

2025/09/03

This year marks the 10th anniversary of Frontiers Health. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley. Stoakes has spent 30+ years at the intersection of tech, science, and design, operating with the focal goal of transforming global health. And Frontiers Health provides a

en-us

23:33

Changing the drug development treatment paradigm:...

pharmaphorum Podcast ·

2025/09/02

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine. Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performance based on size and computing power – apply to biology. You can also listen to episode 202a of the pharmaphorum podcast in the player below, download the

en-us

17:01

Increasing trial efficiency: Adityo Prakash talks...

pharmaphorum Podcast ·

2025/08/28

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient.In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a clinical-stage pharmaceutical company based in Fremont, California that is developing several drug discovery programmes in cardiometabolic diseases and

en-us

13:00

FH25: Ten years at the forefront of health...

pharmaphorum Podcast ·

2025/08/27

This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary. To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation. We’re kicking things off with a very special guest: Kristin Milburn, SVP, marketing ecosystem & strategy at Frontiers Health. Having served

en-us

15:57

MAPs, EAPs, and patient access: Suzanne Aitken on the...

pharmaphorum Podcast ·

2025/08/21

Managed Access Programs (or MAPs) enable mechanisms for patients with unmet medical needs to get access to new medications outside of the clinical trial setting and well before marketing authorisation and reimbursement in a patient's country. Also referred to as Expanded Access Programs and Early Access Programs, these programs are not limited to the US.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of

en-us

35:42

Weighing in on GLP-1 drugs

pharmaphorum Podcast ·

2025/08/19

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go next to the cultural and societal implications of this highly effective treatment for diabetes, weight loss, and potentially much more.On today’s podcast editor-in-chief Jonah Comstock and Deep Dive editor Eloise McLennan forego the usual interview format for an editor-to-editor discussion of a wide variety of topics around GLP-1s. The conversation

en-us

26:34

The TechBio way: Brendan Frey talks genomics, AI, and...

pharmaphorum Podcast ·

2025/08/14

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation

en-us

08:41

Advancing the frontier of cancer diagnostics:...

pharmaphorum Podcast ·

2025/08/12

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the lives of as many people as possible. In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life Sciences, about advancing the frontier of cancer diagnostics and treatment with breakthroughs in AI-driven pathology, real-world clinico-genomic data, and more. These other ASCO 2025 and

en-us

19:18

Compliance baked into the design core: On AI in life...

pharmaphorum Podcast ·

2025/08/07

When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems. The conversation covers commercial model evolution, precision engagement, the importance of quality data in a

en-us

18:40

Putting patients and their families first: Dr Corina...

pharmaphorum Podcast ·

2025/08/05

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer.In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitment to innovation in the oncological field. Tune in to this and other ASCO 2025 conversations here. You can also listen to episode 196a of

en-us

28:19

Enhancing anti-tumour activity: A post-ASCO...

pharmaphorum Podcast ·

2025/07/31

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases. At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC. In a post-ASCO pharmaphorum podcast, Dan Schmitt, CEO of Actuate,

en-us

19:05

Redefining the Future of Melanoma Treatment:...

pharmaphorum Podcast ·

2025/07/29

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how the company develops novel immunotherapy products for the treatment of multiple cancers, as well as its

en-us

280 results

Similar Podcasts

X Minus 1 - Old Time Radio Show

Inception Point Ai

Science, Spoken

WIRED

This Week in Space (Audio)

TWiT

DarshanTalks Podcast

Darshan Kulkarni

The Best of Coast to Coast AM

iHeartPodcasts and Coast to Coast AM